Please assess the completion status of the following clinical trial:

Trial Title: Pulmonary Artery Pressure Reduction With ENTresto (Sacubitril/Valsartan)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients able to provide written informed consent~2. Patients ≥18 years of age, male or female, in NYHA Class II- III HF, previously hospitalized for HFrEF with LVEF \< 35% (measured within the past year), and who have no subsequent LVEF\>35%.~3. Systolic BP \> 95 mm Hg at most recent clinical assessment.~4. Stable, ambulatory patients without the need for change in diuretics and other HF drugs (RAS blockers, beta blockers or mineralocorticoid receptor blockers) during the past 5 days~5. CardioMEMS HF System implanted for NYHA Class III HF. Patient transmitting information regularly and system functioning appropriately.~6. NT-proBNP \> 500 pg/ml within 90 days of CardioMEMS implantation.~7. Average PAPm \>20mm Hg during the 7 days prior to enrollment, including at least 4 daily measurements.~8. Women of childbearing age must be on highly effective method of contraception~Exclusion Criteria:~1. Treatment with vasodilators (other than nitrates, hydralazine) and/or IV inotropic drugs.~2. Entresto taken within the past 30 days.~3. History of hypersensitivity, intolerance or angioedema to previous renin-angiotensin system (RAS) blocker, ACE inhibitor, ARB, or Entresto.~4. eGFR \< 30 ml/min/1.73 m2 as measured by the simplified MDRD formula.~5. Serum potassium \> 5.5 mmol/L.~6. Acute coronary syndrome, stroke, transient ischemic attack, cardiovascular surgery, PCI, or carotid angioplasty within the preceding 3 months.~7. Coronary or carotid artery disease likely to require surgical or percutaneous intervention within 3 months after trial entry.~8. Non-cardiac condition(s) as the primary cause of dyspnea.~9. Implantation of a cardiac resynchronization therapy device (CRT/D) within the pr preceding 3 months or intent to implant a CRT/D, which may alter the pressures during the course of the study.~10. History of heart transplantation, placement of an LVAD, listing for Status IA for cardiac transplantation or planned placement of an LVAD within 3 months following randomization.~11. Documented untreated ventricular arrhythmia with syncopal episodes within the prior 3 months.~12. Symptomatic bradycardia or second or third degree heart block without a pacemaker.~13. Hepatic dysfunction, as evidenced by total bilirubin \> 3 mg/dl.~14. Pregnancy~15. Women who are breastfeeding~16. Chronic lithium use

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group A (Type: EXPERIMENTAL): Group A will receive sacubitril/valsartan + placebo for weeks 1-12. and then sacubitril/valsartan only for weeks 13-32. All subjects in Group A will also receive longitudinal pulmonary artery pressure monitoring using a previously placed implantable hemodynamic monitor (CardioMEMS device).
- Group B (Type: ACTIVE_COMPARATOR): Group B will receive an Angiotensin-Converting Enzyme Inhibitor (ACEi) or Angiotensin II Type 1 Receptor Blocker (ARB) + placebo for weeks 1-6 (depending on previous background therapy) and then switch to sacubitril/valsartan + placebo for weeks 7-12.~Group B will then receive sacubitril/valsartan only for weeks 13-32. All subjects in Group B will also receive longitudinal pulmonary artery pressure monitoring using a previously placed implantable hemodynamic monitor (CardioMEMS device).

Based on this trial design, predict the completion outcome and termination type (if applicable).